Key Indicators of Value and Success in a Life Sciences Company

In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:

• Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
• Evaluating the future impact of key items when reviewing a biotech IP portfolio
• Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
• Valuation methodologies used for early-stage vs. late-stage products

Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.